Alzpath and Quanterix expand strategic licensing agreement for Alzheimer’s biomarker research
QTRX•Alzpath and Quanterix expanded a strategic licensing agreement to advance next-generation Alzheimer’s disease biomarker research.
1. Licensing agreement
Alzpath and Quanterix expanded their strategic licensing agreement to advance next-generation Alzheimer’s disease biomarker research.
